ArticleJournal of hematopathology2026
SSTR2 expression in EBV-positive and EBV-negative lymphomas.
Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSomatostatin receptor 2 (SSTR2) protein expression is aberrantly upregulated in various tumors and can be visualized using scintigraphy or radiological techniques and therapeutically targeted using octreotide-based molecules. PURPOSE: In this study, we assessed SSTR2 expression in the largest cohort of hematopoietic proliferations examined to date and interrogated the relationship between EBV and SSTR2 in EBV-associated lymphomas as a possible mechanism for SSTR2 upregulation.
methodsWe retrospectively identified 407 cases of lymphoma from Guatemala, a country with a high prevalence of EBV-associated lymphomas. SSTR2 protein expression was assessed by immunohistochemistry, while EBV was assessed by in situ hybridization for EBV-associated small RNAs.
resultsWe found SSTR2 expression in 43% (20/47) of EBV-positive classic Hodgkin lymphomas (cHL) and 0% (0/12) of EBV-negative cHL cases. All but one of the other EBV-associated lymphomas (n = 53) were negative for SSTR2. Within the EBV-negative non-Hodgkin lymphomas assessed, 33% (1/3) of diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangement, 17% (25/149) of DLBCL not otherwise specified, and 17% (5/29) of follicular lymphomas showed SSTR2 expression. All other lymphomas showed no significant SSTR2 expression.
conclusionsOur study demonstrates that EBV infection is required, but not sufficient, to upregulate SSTR2 in classic Hodgkin lymphoma, but not in other EBV-associated lymphomas. We also provide data to suggest that SSTR2 is associated with "higher-grade" germinal center-derived B-cell lymphomas in EBV-negative non-Hodgkin lymphomas.
Indexed as
Identifiers
41963561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.